The FAST III Trial: Revolutionizing Cardiac Care with CAAS vFFR Technology

In a significant advancement for cardiac treatments, the FAST III trial, initiated five years ago, has concluded, demonstrating the effectiveness of revascularization guided by CAAS vFFR (vessel Fractional Flow Reserve) compared to the conventional pressure wire-based FFR (Fractional Flow Reserve). The results were unveiled in the prestigious New England Journal of Medicine and presented during the American College of Cardiology (ACC) 2026 Congress. This trial embodies a key milestone in cardiology, confirming that angiography-based vFFR is a safe, effective alternative for assessing coronary lesions.

The FAST III trial, an open-label and multicenter randomized study, involved 2,235 patients who exhibited intermediate coronary lesions—defined as those with 30% to 80% stenosis as determined visually or via Quantitative Coronary Angiography (QCA). The patients were assessed using the CAAS vFFR or traditional pressure wire methods and treated when the vFFR or FFR results were less than or equal to 0.80.

The primary objective was to evaluate the rates of major adverse cardiovascular events (MACE) over one year, including all-cause death, myocardial infarction, or the need for any further revascularization.

Under the leadership of principal investigator Dr. Joost Daemen at the Erasmus University Medical Center in Rotterdam, the trial successfully met its primary endpoint. Both the vFFR-guided group and the standard FFR-guided group showed identical rates of MACE, marking the study's success. According to Daemen, “The results of FAST III confirm the safety and feasibility of the online use of vFFR as an easy-to-use minimally invasive tool to guide revascularization in patients with intermediate coronary artery lesions.” He added that this technological innovation could elevate the assessment standards—enhancing decision-making around revascularization, which has often relied on less precise visual evaluations.

Moreover, Bas Kuppens, CEO of Pie Medical Imaging, referred to the FAST III trial results as a significant turning point in cardiac care. He noted, “It confirms that angiography-based physiology is non-inferior to traditional pressure wire-based physiology,” adding that the findings herald closer patient care with lower doses of contrast agent, reduced procedural times, and the mitigation of discomfort associated with invasive methods.

Doris Pommi, head of Cardiovascular Care at Siemens Healthineers, also hailed the results as a major breakthrough, emphasizing the partnership between Siemens and Pie Medical Imaging. “The success illustrates what collaborations can achieve when combining clinical experience, scientific excellence, and industrial innovation,” she stated.

In today's healthcare landscape, it's crucial to prioritize less invasive methods that enhance patient comfort while maintaining diagnostic accuracy. The findings from the FAST III trial are poised to influence reimbursement policies for these less invasive evaluation techniques in patients with intermediate coronary stenosis, potentially making advanced cardiac care more accessible.

The clinical implications are extensive. With the ability to evaluate physiological parameters without invasive catheters or hyperemic agents, vFFR technology minimizes risks and improves patient experiences. This could not only streamline the procedural protocols but also enable healthcare providers to deliver more efficient care.

Pie Medical Imaging, situated in Maastricht, Netherlands, leads the charge in cardiac imaging analysis innovation and product development, showcasing its commitment to improving clinical outcomes through advanced diagnosis and intervention methods.

In conclusion, the FAST III study signifies a pivotal step forward in cardiac healthcare, affirming the viability of using CAAS vFFR as an alternative to traditional FFR techniques. As research continues to unfold, the implications of this trial may pave the way for fundamental changes in coronary artery disease management, fostering environments where safer, faster, and less uncomfortable diagnostic assessments are now within reach.